22 research outputs found
Genetic analysis of nucleotide sequences of neuraminidase gene of highly pathogenic avian influenza A/H5N8 virus isolates recovered in the Russian Federation in 2020
Avian influenza is a highly dangerous viral disease that causes huge economic damage to poultry farming. Currently, highly virulent influenza virus with N8 neur- aminidase subtype is quite often detected in populations of domestic and wild birds in various countries of the world. The article provides data on complete nucleotide sequences of the neuraminidase gene of highly pathogenic avian influenza virus isolates recovered in the second half of 2020 from pathological material received from four regions of the Russian Federation. The conducted research showed that the subtype of the isolated virus was N8. According to the phylogenetic analysis, isolates of N8 virus belong to group 8C.4. During the phylogenetic analysis of the neuraminidase, we also took into account data on hemagglutinin classification, according to which H5N8 virus isolates belong to a widespread clade 2.3.4.4. Viruses of the clade were first registered in 2010 in China and they have been circulating up to now. The paper also provides data of a comparative analysis of nucleotide sequences of the studied isolates and the isolates from the international GenBank and GISAID databases, recovered in other countries from 2007 to 2020. During the analysis of the amino acid sequence of the studied isolates, no substitutions were found in the positions that affect resistance to neuraminidase inhibitors. The complete nucleotide sequences of the neuraminidase gene of the avian influenza virus subtype N8 (isolates A/domestic goose/OMSK/1521-1/2020, A/duck/Chelyabinsk/1207-1/2020, A/duck/Saratov/1578-2/2020, A/goose/Tatarstan/1730-2/2020) are published in the international GenBank and GISAID databases. Based on the analysis of the nucleotide sequences of the studied isolates, the article shows gradual evolution of the N8 subtype virus
Non-perturbative Renormalisation of Domain Wall Fermions: Quark Bilinears
We find the renormalisation coefficients of the quark field and the flavour
non-singlet fermion bilinear operators for the domain wall fermion action, in
the regularisation independent (RI) renormalisation scheme. Our results are
from a quenched simulation, on a 16^3x32 lattice, with beta=6.0 and an extent
in the fifth dimension of 16. We also discuss the expected effects of the
residual chiral symmetry breaking inherent in a domain wall fermion simulation
with a finite fifth dimension, and study the evidence for both explicit and
spontaneous chiral symmetry breaking effects in our numerical results. We find
that the relations between different renormalisation factors predicted by
chiral symmetry are, to a good approximation, satisfied by our results and that
systematic effects due to the (low energy) spontaneous chiral symmetry breaking
and zero-modes can be controlled. Our results are compared against the
perturbative predictions for both their absolute value and renormalisation
scale dependence.Comment: 53 pages, 21 figures, revte
ΠΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΏΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΠΎΠΉ 13-Π²Π°Π»Π΅Π½ΡΠ½ΠΎΠΉ ΠΊΠΎΠ½ΡΡΠ³ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ Π²Π°ΠΊΡΠΈΠ½Ρ Ρ Π²Π·ΡΠΎΡΠ»ΡΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π±ΡΠΎΠ½Ρ ΠΎΠ»Π΅Π³ΠΎΡΠ½ΠΎΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠ΅ΠΉ
Aim. The aim of this study was to investigate safety and clinical efficacy of 13valent conjugated pneumococcal vaccine (PCV13) and 23valent polyΒ saccharide pneumococcal vaccine (PPV23) in patients with chronic obstructive pulmonary disease (COPD) and asthma and to assess impact of vaccination on quality on life.Β Methods. This was a prospective comparative study. Clinical efficacy and safety were evaluated using data on systemic and local adverse reactionsΒ during a month after vaccination, changes in lung function and quality of life (QoL in 6 months after vaccination. Lung function was assessed beforeΒ and 1 and 6 months after vaccination. QoL was measured before and 6 months after vaccination using CAT test in COPD patients and ACQ quesΒ tionnaire in asthma patients.Β Results. The study involved 58 patients with COPD and 59 patients with asthma. Of them, 33 and 34 patients, respectively, were vaccinated withΒ PCV13 and 25 patients of each group were vaccinated with PPV23. A rate of systemic and local adverse reactions did not differ significantly betweenΒ patients vaccinated with PCV13 or PPV23. Patients with both COPD and asthma vaccinated with PCV13 demonstrated more significant increaseΒ in FEV1. QoL improved in all vaccinated patients. Worsening of the disease was not noted in any patient.Conclusion. In patients with COPD and asthma, lung function tended to improvement and QoL significantly improved in 6 months after vaccinaΒ tion with PCV13 or PPV23. Both vaccines were well tolerated.ΠΡΠΎΠ±Π»Π΅ΠΌΠ° Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ ΠΏΡΠΎΡΠΈΠ² ΠΏΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π±ΡΠΎΠ½Ρ
ΠΎΠ»Π΅Π³ΠΎΡΠ½ΠΎΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠ΅ΠΉ ΡΠ²Π»ΡΠ΅ΡΡΡ Π°ΠΊΡΡΠ°Π»ΡΠ½ΠΎΠΉ, Ρ. ΠΊ. ΠΏΡΠΈ Π΄Π°Π½Π½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΠΎΠ±ΠΎΡΡΡΡΠ΅ΡΡΡ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΎΡΠ½ΠΎΠ²Π½ΠΎΠ³ΠΎ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ, ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΡΠ΅Ρ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΏΡΠΎΡΠ΅ΡΡ, ΡΡ
ΡΠ΄ΡΠ°Π΅ΡΡΡ ΠΊΠ°ΡΠ΅ΡΡΠ²ΠΎ ΠΆΠΈΠ·Π½ΠΈ (ΠΠ)Β Π±ΠΎΠ»ΡΠ½ΡΡ
.Β ΠΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΠΎ ΠΎΡΠ΅Π½ΠΊΠ΅ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ, ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΡΡΠ΅ΠΊΡΠ°, Π²Π»ΠΈΡΠ½ΠΈΡ Π½Π° ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΠΠ 13Π²Π°Π»Π΅Π½ΡΠ½ΠΎΠΉΒ ΠΊΠΎΠ½ΡΡΠ³ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ (ΠΠΠ-13) ΠΈ 23Π²Π°Π»Π΅Π½ΡΠ½ΠΎΠΉ ΠΏΠΎΠ»ΠΈΡΠ°Ρ
Π°ΡΠΈΠ΄Π½ΠΎΠΉ ΠΏΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΡΡ
Π²Π°ΠΊΡΠΈΠ½ (ΠΠΠ-23) Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π±ΡΠΎΠ½Ρ
ΠΎΠ»Π΅Β Π³ΠΎΡΠ½ΠΎΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠ΅ΠΉ.Β ΠΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ Ρ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΡΡ Π»Π΅Π³ΠΊΠΈΡ
(Π₯ΠΠΠ) (n = 58) ΠΈ Π±ΡΠΎΠ½Ρ
ΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π°ΡΡΠΌΠΎΠΉ (ΠΠ) (n = 59). ΠΠΠ-13Β Π±ΡΠ»ΠΈ Π²Π°ΠΊΡΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ Ρ Π₯ΠΠΠ (n = 33) ΠΈ ΠΠ (n = 34), Π° ΠΠΠ-23 β ΠΏΠΎ 25 Π±ΠΎΠ»ΡΠ½ΡΡ
Π₯ΠΠΠ ΠΈ ΠΠ. Π ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΠΎΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ Π½Π΅Β Π²ΡΡΠ²Π»Π΅Π½ΠΎ ΡΠ°Π·Π»ΠΈΡΠΈΠΉ Π² ΡΠ°ΡΡΠΎΡΠ΅ Π²ΠΎΠ·Π½ΠΈΠΊΠ½ΠΎΠ²Π΅Π½ΠΈΡ ΡΠΈΡΡΠ΅ΠΌΠ½ΡΡ
ΠΈ ΠΌΠ΅ΡΡΠ½ΡΡ
ΡΠ΅Π°ΠΊΡΠΈΠΉ ΠΏΡΠΈ Π²Π²Π΅Π΄Π΅Π½ΠΈΠΈ ΠΊΠΎΠ½ΡΡΠ³ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΈ ΠΏΠΎΠ»ΠΈΡΠ°Ρ
Π°ΡΠΈΠ΄Π½ΠΎΠΉ ΠΏΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΡΡ
Π²Π°ΠΊΡΠΈΠ½. Π£ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΊΠ°ΠΊ Π₯ΠΠΠ, ΡΠ°ΠΊ ΠΈ ΠΠ Π±ΡΠ»Π° Π²ΡΡΠ²Π»Π΅Π½Π° Π±ΠΎΠ»Π΅Π΅ Π²ΡΡΠ°ΠΆΠ΅Π½Π½Π°Ρ ΡΠ΅Π½Π΄Π΅Π½ΡΠΈΡ ΠΊ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΡ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Ρ ΠΎΠ±ΡΠ΅ΠΌΠ° ΡΠΎΡΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ Π²ΡΠ΄ΠΎΡ
Π° Π·Π° 1Ρ ΡΠ΅ΠΊΡΠ½Π΄Ρ Π² Π³ΡΡΠΏΠΏΠ°Ρ
, Π²Π°ΠΊΡΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΠΠ-13. ΠΠΎΡΠ»Π΅ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΠΎΠΉ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ Π±ΡΠ»ΠΎ ΠΎΡΠΌΠ΅ΡΠ΅Π½ΠΎ ΡΠ»ΡΡΡΠ΅Π½ΠΈΠ΅Β ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΠΠ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π²ΠΎ Π²ΡΠ΅Ρ
Π³ΡΡΠΏΠΏΠ°Ρ
. Π‘Π»ΡΡΠ°Π΅Π² ΡΡ
ΡΠ΄ΡΠ΅Π½ΠΈΡ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΠΎΡΠ½ΠΎΠ²Π½ΠΎΠ³ΠΎ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ Π½Π΅ Π·Π°ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π½ΠΎ
ΠΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΌΠΈΠΊΡΠΎΠ±Π½ΠΎΠ³ΠΎ ΠΏΠ΅ΠΉΠ·Π°ΠΆΠ° ΠΌΠΎΠΊΡΠΎΡΡ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΡΡ Π»Π΅Π³ΠΊΠΈΡ Π½Π° ΡΠΎΠ½Π΅ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ ΠΏΡΠΎΡΠΈΠ² ΠΏΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΊΠ°, Π³Π΅ΠΌΠΎΡΠΈΠ»ΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΡΠΈΠΏΠ° b ΠΈ Π³ΡΠΈΠΏΠΏΠ°
Summary. The influence of combined vaccination against Streptococcus pneumoniae, Haemophilus influenzae type b and influenza on sputum bacterial land scape in patients with chronic obstructive pulmonary disease (COPD) has been analyzed in this article. The 1st group of 31 COPD patients (mean age, 59.25 Β± 1.12 years) were vaccinated simultaneously with "Pneumo23", "Hiberix", "Grippol plus". The 2nd group consisted of 49 unvaccinated COPD patients (mean age, 57.16 Β± 0.98 years). We used a classical microbiological method. Three months after the complete vaccination, there was a significant decrease in number of patients with S. pneumoniae yielded in sputum in comparison with unvaccinated COPD patients.Π Π΅Π·ΡΠΌΠ΅. Π¦Π΅Π»ΡΡ ΡΠ°Π±ΠΎΡΡ Π±ΡΠ»ΠΎ ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ Π²Π»ΠΈΡΠ½ΠΈΡ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΉ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ ΠΏΡΠΎΡΠΈΠ² ΠΏΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΊΠ°, Π³Π΅ΠΌΠΎΡΠΈΠ»ΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΡΠΈΠΏΠ° b ΠΈ Π³ΡΠΈΠΏΠΏΠ° Π½Π° ΠΌΠΈΠΊΡΠΎΠ±Π½ΡΠΉ ΠΏΠ΅ΠΉΠ·Π°ΠΆ ΠΌΠΎΠΊΡΠΎΡΡ ΡΠ΅ΡΠ΅Π· 3 ΠΌΠ΅Ρ. ΠΏΠΎΡΠ»Π΅ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΡΡ Π»Π΅Π³ΠΊΠΈΡ
(Π₯ΠΠΠ) ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ Π½Π΅Π²Π°ΠΊΡΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌΠΈ. ΠΠ΅ΡΠ²ΡΡ Π³ΡΡΠΏΠΏΡ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ Ρ Π₯ΠΠΠ (n = 31), ΠΎΠ΄Π½ΠΎΠΌΠΎΠΌΠ΅Π½ΡΠ½ΠΎ Π²Π°ΠΊΡΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ "ΠΠ½Π΅Π²ΠΌΠΎ23", "Π₯ΠΈΠ±Π΅ΡΠΈΠΊΡ", "ΠΡΠΈΠΏΠΏΠΎΠ» ΠΏΠ»ΡΡ" (ΡΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ β 59,25 Β± 1,12 Π³ΠΎΠ΄Π°), Π²ΡΠΎΡΡΡ Π³ΡΡΠΏΠΏΡ β Π½Π΅Π²Π°ΠΊΡΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ Ρ Π₯ΠΠΠ (n = 49) (ΡΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ β 57,16 Β± 0,98 Π³ΠΎΠ΄Π°). ΠΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΡΡ ΠΊΠ»Π°ΡΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΌΠΈΠΊΡΠΎΠ±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΌΠ΅ΡΠΎΠ΄. Π§Π΅ΡΠ΅Π· 3 ΠΌΠ΅Ρ. ΠΠΎΡΠ»Π΅ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΉ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ ΠΎΡΠΌΠ΅ΡΠ΅Π½ΠΎ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎΠ΅ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ ΡΠΈΡΠ»Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², Π²ΡΠ΄Π΅Π»ΡΡΡΠΈΡ
Ρ ΠΌΠΎΠΊΡΠΎΡΠΎΠΉ Streptococcus pneumoniae, ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ Π½Π΅Π²Π°ΠΊΡΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌΠΈ Π±ΠΎΠ»ΡΠ½ΡΠΌΠΈ Π₯ΠΠΠ
Domain wall fermion zero modes on classical topological backgrounds
The domain wall approach to lattice fermions employs an additional dimension,
in which gauge fields are merely replicated, to separate the chiral components
of a Dirac fermion. It is known that in the limit of infinite separation in
this new dimension, domain wall fermions have exact zero modes, even for gauge
fields which are not smooth. We explore the effects of finite extent in the
fifth dimension on the zero modes for both smooth and non-smooth topological
configurations and find that a fifth dimension of around ten sites is
sufficient to clearly show zero mode effects. This small value for the extent
of the fifth dimension indicates the practical utility of this technique for
numerical simulations of QCD.Comment: Updated fig. 3-7, small changes in sect. 3, added fig. 8, added more
reference
The finite temperature QCD phase transition with domain wall fermions
The domain wall formulation of lattice fermions is expected to support
accurate chiral symmetry, even at finite lattice spacing. Here we attempt to
use this new fermion formulation to simulate two-flavor, finite temperature QCD
near the chiral phase transition. In this initial study, a variety of quark
masses, domain wall heights and domain wall separations are explored using an
8^3 x 4 lattice. Both the expectation value of the Wilson line and the chiral
condensate show the temperature dependence expected for the QCD phase
transition. Further, the desired chiral properties are seen for the chiral
condensate, suggesting that the domain wall fermion formulation may be an
effective approach for the numerical study of QCD at finite temperature.Comment: 44 pages, 15 figure
Π―Π²Π»ΡΠ΅ΡΡΡ Π»ΠΈ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½Π°Ρ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΡ ΠΏΡΠΎΡΠΈΠ² ΡΠ΅ΡΠΏΠΈΡΠ°ΡΠΎΡΠ½ΡΡ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈΜ ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΡΠΌ ΡΠ°ΠΊΡΠΎΡΠΎΠΌ Π² ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠΈ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ°ΡΡΡΠ° Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΈΜ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎΠΈΜ Π±ΠΎΠ»Π΅Π·Π½ΡΡ Π»Π΅Π³ΠΊΠΈΡ ?
The aim of this study was to compare functional status of patients with chronic obstructive pulmonary disease (COPD) vaccinated by combined vaccine vs single vaccine against influenza and a control group. Methods. The study involved 170 patients with COPD stage I to IV. Of them, 50 patients were vaccinated with a combined vaccine against pneumococcus, Haemophilus influenzae type b and influenza; 80 patients with equal COPD severity were not vaccinated and were treated with basic therapy; 20 COPD patients were vaccinated with a single vaccine against influenza, and 20 COPD patients were not vaccinated. Lung function and physical tolerability at 6-min walk test were assessed at baseline and in 12 months. Results. A significantly higher FEV1 (57.4 Β± 2.0 % vs 50.4 Β± 2.8 %) was found in COPD patients vaccinated with a combined vaccine compared to unvaccinated COPD patients; the difference between baseline FEV1 and FEV1 in 12 months after vaccination was 3.5 % vs 2.11 %, respectively. The improvement in 6-min distance was + 34 m (+ 7.4 %) in combined vaccine group compared to + 13 m (+ 3.7 %) in influenza vaccine group. Conclusion. COPD patients vaccinated with a combined vaccine against bacterial pathogens plus influenza better improved their lung function and physical tolerability compared to COPD patients vaccinated with a single vaccine against influenza.ΠΡΠΈΠ²ΠΎΠ΄ΡΡΡΡ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΠΏΠΎ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠ΅ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΡΠ΅ΡΡΠΎΠ² Π½Π° ΡΠΎΠ½Π΅ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΈΜ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ ΠΏΡΠΎΡΠΈΠ² ΠΏΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΠΎΠΈΜ, Π³Π΅ΠΌΠΎΡΠΈΠ»ΡΠ½ΠΎΠΈΜ ΡΠΈΠΏΠ° b ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈΜ ΠΈ Π³ΡΠΈΠΏΠΏΠ° ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΌΠΎΠ½ΠΎΠ²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠ΅ΠΈΜ ΠΏΡΠΎΡΠΈΠ² Π³ΡΠΈΠΏΠΏΠ° Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΈΜ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎΠΈΜ Π±ΠΎΠ»Π΅Π·Π½ΡΡ Π»Π΅Π³ΠΊΠΈΡ
(Π₯ΠΠΠ). ΠΡΠΎΠ²Π΅Π΄Π΅Π½Π° ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½Π°Ρ ΠΎΡΠ΅Π½ΠΊΠ° Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠΈ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΡΠ΅ΡΡΠΎΠ² Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π₯ΠΠΠ Π½Π° ΡΠΎΠ½Π΅ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΈΜ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ, ΠΌΠΎΠ½ΠΎΠ²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ ΠΏΡΠΎΡΠΈΠ² Π³ΡΠΈΠΏΠΏΠ° Π² ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΈ Ρ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΈΜ Π³ΡΡΠΏΠΏΠΎΠΈΜ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΡΡΠ°ΡΡΠ²ΠΎΠ²Π°Π»ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ (n = 170) Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ ΠΎΡ 30 Π»Π΅Ρ Ρ Π₯ΠΠΠ IβIV ΡΡΠ΅ΠΏΠ΅Π½ΠΈ: Π² 1-Ρ Π³ΡΡΠΏΠΏΡ (n = 50) Π²ΠΊΠ»ΡΡΠ΅Π½Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ, ΠΏΠΎΠ»ΡΡΠΈΠ²ΡΠΈΠ΅ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΡΡ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΡ ΠΏΡΠΎΡΠΈΠ² ΠΏΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΠΎΠΈΜ, Π³Π΅ΠΌΠΎΡΠΈΠ»ΡΠ½ΠΎΠΈΜ ΡΠΈΠΏΠ° b ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈΜ ΠΈ Π³ΡΠΈΠΏΠΏΠ°; Π²ΠΎ 2-Ρ (n = 80) β Π½Π΅Π²Π°ΠΊΡΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ ΠΈ ΠΏΠΎΠ»ΡΡΠ°Π²ΡΠΈΠ΅ ΡΠΎΠ»ΡΠΊΠΎ Π±Π°Π·ΠΈΡΠ½ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ; Π² 3-Ρ (n = 20) β ΠΏΡΠΈΠ²ΠΈΡΡΠ΅ ΠΏΡΠΎΡΠΈΠ² Π³ΡΠΈΠΏΠΏΠ°; Π² 4-Ρ (n = 20) β Π½Π΅ΠΏΡΠΈΠ²ΠΈΡΡΠ΅. ΠΡΡ
ΠΎΠ΄Π½ΠΎ ΠΈ ΡΠ΅ΡΠ΅Π· 12 ΠΌΠ΅Ρ. ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈΡΡ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΡΠ΅ΡΡΠΎΠ² (ΡΠΎΡΡΠΈΡΠΎΠ²Π°Π½Π½Π°Ρ ΠΆΠΈΠ·Π½Π΅Π½Π½Π°Ρ Π΅ΠΌΠΊΠΎΡΡΡ Π»Π΅Π³ΠΊΠΈΡ
β Π€ΠΠΠ, ΠΎΠ±ΡΠ΅ΠΌ ΡΠΎΡΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ Π²ΡΠ΄ΠΎΡ
Π° Π·Π° 1-Ρ ΡΠ΅ΠΊΡΠ½Π΄Ρ β ΠΠ€Π1, ΠΈΠ½Π΄Π΅ΠΊΡ Π’ΠΈΡΡΠ½ΠΎ β ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠ΅ ΠΠ€Π1 / Π€ΠΠΠ, 6-ΠΌΠΈΠ½ΡΡΠ½ΡΠΈΜ ΡΠ°Π³ΠΎΠ²ΡΠΈΜ ΡΠ΅ΡΡ β 6-ΠΠ¨Π’). Π Π³ΡΡΠΏΠΏΠ΅ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΈΜ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ ΡΠ΅ΡΠ΅Π· 12 ΠΌΠ΅Ρ. ΠΎΡΠΌΠ΅ΡΠ΅Π½ΠΎ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ Π±ΠΎΠ»ΡΡΠ΅Π΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ ΠΠ€Π1 (57,4 Β± 2,0 %) ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ Π½Π΅ΠΏΡΠΈΠ²ΠΈΡΡΠΌΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌΠΈ Ρ Π₯ΠΠΠ (50,4 Β± 2,8 %). ΠΡΠΈΡΠΎΡΡ ΠΎΡΠ½ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Ρ ΠΠ€Π1 Π² Π³ΡΡΠΏΠΏΠ΅ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΈΜ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ ΡΠΎΡΡΠ°Π²ΠΈΠ» 3,5 %. Π Π³ΡΡΠΏΠΏΠ΅ ΠΌΠΎΠ½ΠΎΠ²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ ΠΏΡΠΎΡΠΈΠ² Π³ΡΠΈΠΏΠΏΠ° ΠΏΡΠΈΡΠΎΡΡ ΠΠ€Π1 ΡΠΎΡΡΠ°Π²ΠΈΠ» 2,11 %. ΠΡΠΈΡΠΎΡΡ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Ρ 6-ΠΠ¨Π’ Π·Π° 12 ΠΌΠ΅Ρ. Π² 1-ΠΈΜ Π³ΡΡΠΏΠΏΠ΅ ΡΠΎΡΡΠ°Π²ΠΈΠ» 7,4 % (+ 34 ΠΌ) (Ρ < 0,05). Π§Π΅ΡΠ΅Π· 12 ΠΌΠ΅Ρ. ΠΏΠΎΡΠ»Π΅ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ ΠΏΡΠΎΡΠΈΠ² Π³ΡΠΈΠΏΠΏΠ° Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Π₯ΠΠΠ Π²ΡΡΠ²Π»Π΅Π½Π° ΡΠ΅Π½Π΄Π΅Π½ΡΠΈΡ ΠΊ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΡ ΠΏΡΠΎΠΈΜΠ΄Π΅Π½Π½ΠΎΠΈΜ Π΄ΠΈΡΡΠ°Π½ΡΠΈΠΈ Π½Π° 13 ΠΌ (+ 3,7 %) (Ρ > 0,05). ΠΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½Π°Ρ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π₯ΠΠΠ ΠΏΡΠΎΡΠΈΠ² Π±Π°ΠΊΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΡΡ
ΡΠ΅ΡΠΏΠΈΡΠ°ΡΠΎΡΠ½ΡΡ
ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈΜ ΠΈ Π³ΡΠΈΠΏΠΏΠ° ΡΠΏΠΎΡΠΎΠ±ΡΡΠ²ΡΠ΅Ρ Π±ΠΎΠ»ΡΡΠ΅ΠΌΡ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΡ ΠΠ€Π1, Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎΠΌΡ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΡ Π΄ΠΈΡΡΠ°Π½ΡΠΈΠΈ 6-ΠΠ¨Π’ ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ Π»ΠΈΡΠ°ΠΌΠΈ, Π²Π°ΠΊΡΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌΠΈ ΡΠΎΠ»ΡΠΊΠΎ ΠΏΡΠΎΡΠΈΠ² Π³ΡΠΈΠΏΠΏΠ°.
Quenched Lattice QCD with Domain Wall Fermions and the Chiral Limit
Quenched QCD simulations on three volumes, , and
and three couplings, , 5.85 and 6.0 using domain
wall fermions provide a consistent picture of quenched QCD. We demonstrate that
the small induced effects of chiral symmetry breaking inherent in this
formulation can be described by a residual mass (\mres) whose size decreases
as the separation between the domain walls () is increased. However, at
stronger couplings much larger values of are required to achieve a given
physical value of \mres. For and , we find
\mres/m_s=0.033(3), while for , and ,
\mres/m_s=0.074(5), where is the strange quark mass. These values are
significantly smaller than those obtained from a more naive determination in
our earlier studies. Important effects of topological near zero modes which
should afflict an accurate quenched calculation are easily visible in both the
chiral condensate and the pion propagator. These effects can be controlled by
working at an appropriately large volume. A non-linear behavior of in
the limit of small quark mass suggests the presence of additional infrared
subtlety in the quenched approximation. Good scaling is seen both in masses and
in over our entire range, with inverse lattice spacing varying between
1 and 2 GeV.Comment: 91 pages, 34 figure
Π‘ΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠΈ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° ΠΆΠΈΠ·Π½ΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΡΡ Π»Π΅Π³ΠΊΠΈΡ Π½Π° ΡΠΎΠ½Π΅ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ ΠΏΡΠΎΡΠΈΠ² ΠΏΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ 13-Π²Π°Π»Π΅Π½ΡΠ½ΠΎΠΉ ΠΊΠΎΠ½ΡΡΠ³ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΈ 23-Π²Π°Π»Π΅Π½ΡΠ½ΠΎΠΉ ΠΏΠΎΠ»ΠΈΡΠ°Ρ Π°ΡΠΈΠ΄Π½ΠΎΠΉ Π²Π°ΠΊΡΠΈΠ½
The aim of this study was to evaluate an impact of 13-valent conjugate pneumococcal vaccine (PCV-13) and 23-valent polysaccharide pneumococcal vaccine (PPV-23) on quality of life of patients with chronic obstructive pulmonary disease. Methods. We estimated quality of life from baseline to 12 months after the vaccination using the COPD Assessment Test (CAT). Results. The study involved 58 patients with COPD vaccinated with PCV-13 (n = 33) or PPV-23 (n = 25). The CAT score reduced by 10.3 in patients vaccinated with PCV-13 and by 8.8 in patients vaccinated with PPV-23 (p < 0.05). Conclusion. Vaccination of COPD patients with PCV-13 or PPV-23 could significantly improve quality of life. The conjugate vaccine PCV-13 is more preferable. Further studies of microbiological, immunological and other effects of PCV-13 and PPV-23 in COPD patients are needed.ΠΡΠΈΠ²ΠΎΠ΄ΡΡΡΡ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠΈ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° ΠΆΠΈΠ·Π½ΠΈ (ΠΠ) Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΡΡ Π»Π΅Π³ΠΊΠΈΡ
(Π₯ΠΠΠ) Π½Π° ΡΠΎΠ½Π΅ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ ΠΏΡΠΎΡΠΈΠ² ΠΏΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ 13-Π²Π°Π»Π΅Π½ΡΠ½ΠΎΠΉ ΠΊΠΎΠ½ΡΡΠ³ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ Π²Π°ΠΊΡΠΈΠ½Ρ Β«ΠΡΠ΅Π²Π΅Π½Π°Ρ-13Β» (ΠΠΠ-13) ΠΈΠ»ΠΈ 23-Π²Π°Π»Π΅Π½ΡΠ½ΠΎΠΉ ΠΏΠΎΠ»ΠΈΡΠ°Ρ
Π°ΡΠΈΠ΄Π½ΠΎΠΉ Π²Π°ΠΊΡΠΈΠ½Ρ Β«ΠΠ½Π΅Π²ΠΌΠΎ-23Β» (ΠΠΠ-23). Π¦Π΅Π»Ρ: ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½Π°Ρ ΠΎΡΠ΅Π½ΠΊΠ° Π²Π»ΠΈΡΠ½ΠΈΡ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ ΠΏΡΠΎΡΠΈΠ² ΠΏΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Π½Π° ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΠΠ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π₯ΠΠΠ Π·Π° 12 ΠΌΠ΅Ρ. ΠΏΡΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠΈ ΠΠΠ-13 ΠΈ ΠΠΠ-23. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΠΏΡΠΈΠ½ΡΠ»ΠΈ ΡΡΠ°ΡΡΠΈΠ΅ Β ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ Ρ Π₯ΠΠΠ (n = 58). ΠΠ°ΡΠΈΠ΅Π½ΡΡ, ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΡΡΡΠΈΠ΅ ΠΊΡΠΈΡΠ΅ΡΠΈΡΠΌ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΈΡ / ΠΈΡΠΊΠ»ΡΡΠ΅Π½ΠΈΡ, Π² Π°ΠΌΠ±ΡΠ»Π°ΡΠΎΡΠ½ΡΡ
ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΠΏΠΎΠ»ΡΡΠΈΠ»ΠΈ Π²Π½ΡΡΡΠΈΠΌΡΡΠ΅ΡΠ½ΠΎ Π² Π»Π΅Π²ΠΎΠ΅ ΠΏΠ»Π΅ΡΠΎ 1 Π΄ΠΎΠ·Ρ Π²Π°ΠΊΡΠΈΠ½Ρ ΠΠΠ-13 (1-Ρ Π³ΡΡΠΏΠΏΠ°; n = 33) Π»ΠΈΠ±ΠΎ ΠΠΠ-23 (2-Ρ Π³ΡΡΠΏΠΏΠ°; n = 25). ΠΡΠ΅Π½ΠΈΠ²Π°Π»Π°ΡΡ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠ° ΠΠ Π²Π°ΠΊΡΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ COPD Assessment Test (Π‘ΠΠ’) Π·Π° 1 Π³ΠΎΠ΄ Π΄ΠΎ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ ΠΈ Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ 1 Π³ΠΎΠ΄Π° ΠΏΠΎΡΠ»Π΅. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΡΠΈ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π₯ΠΠΠ ΠΠΠ-13 ΠΎΡΠΌΠ΅ΡΠ΅Π½ΠΎ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ Π‘ΠΠ’ Π½Π° 10,3 Π±Π°Π»Π»Π°; Π² Π³ΡΡΠΏΠΏΠ΅ ΠΠΠ-23 Π΄Π°Π½Π½ΡΠΉ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Ρ ΡΠ½ΠΈΠ·ΠΈΠ»ΡΡ Π½Π° 8,8 Π±Π°Π»Π»Π° (Ρ < 0,05). ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠ°ΠΊΡΠΈΠ½Π°ΡΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ Π₯ΠΠΠ ΠΏΡΠΎΡΠΈΠ² ΠΏΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΠΠ-13 ΠΈΠ»ΠΈ ΠΠΠ-23 ΡΠΏΠΎΡΠΎΠ±ΡΡΠ²ΡΠ΅Ρ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎΠΌΡ ΡΠ»ΡΡΡΠ΅Π½ΠΈΡ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΠΠ. ΠΡΠΈ Π½Π°Π»ΠΈΡΠΈΠΈ Π²ΡΠ±ΠΎΡΠ° Π²Π²Π΅Π΄Π΅Π½ΠΈΡ ΠΠΠ-13 ΠΈΠ»ΠΈ ΠΠΠ-23 Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π₯ΠΠΠ ΡΠ»Π΅Π΄ΡΠ΅Ρ ΠΎΡΠ΄Π°Π²Π°ΡΡ ΠΏΡΠ΅Π΄ΠΏΠΎΡΡΠ΅Π½ΠΈΠ΅ Π² ΠΏΠΎΠ»ΡΠ·Ρ ΠΊΠΎΠ½ΡΡΠ³ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ Π²Π°ΠΊΡΠΈΠ½Π½ΠΎΠ³ΠΎ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°. Π’ΡΠ΅Π±ΡΡΡΡΡ Π΄ΠΎΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΌΠΈΠΊΡΠΎΠ±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ, ΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈ Π΄ΡΡΠ³ΠΈΡ
ΡΡΡΠ΅ΠΊΡΠΎΠ² ΠΏΡΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠΈ ΠΠΠ-13 ΠΈ ΠΠΠ-23 Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π₯ΠΠΠ, Π° Π½Π΅ ΡΠΎΠ»ΡΠΊΠΎ Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π½Π° ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΠΠ